公开(公告)号：US10308986B2

公开(公告)日：2019-06-04

申请号：US14774772

申请日：2014-03-13

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION ,  THE BRIGHAM AND WOMEN'S HOSPITAL, INC. ,  DANA-FARBER CANCER INSTITUTE, INC. ,  THE TECHNICAL UNIVERSITY OF DENMARK

Inventor： Zoltan I. Szallasi ,  Andrea L. Richardson ,  Nicolai J. Birkbak ,  Zhigang Wang

IPC: A61K31/282 ,  A61K33/24 ,  C12Q1/6886 ,  G01N33/574 ,  A61K31/704

Abstract: The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.

公开(公告)号：US20170037478A1

公开(公告)日：2017-02-09

申请号：US15298728

申请日：2016-10-20

Applicant: DANA-FARBER CANCER INSTITUTE, INC. ,  THE BRIGHAM AND WOMEN'S HOSPITAL, INC. ,  CHILDREN'S MEDICAL CENTER CORPORATION ,  THE TECHNICAL UNIVERSITY OF DENMARK

Inventor： Andrea L. Richardson ,  Zhigang C. Wang ,  Daniel P. Silver ,  Zoltan Szallasi ,  Nicolai Juul Birkbak ,  Aron Charles Eklund

IPC: C12Q1/68

Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.

Abstract translation: 本发明部分地基于鉴定用于定义对抗癌药物的响应的预测生物标志物的新方法。

公开(公告)号：US20220186311A1

公开(公告)日：2022-06-16

申请号：US17683656

申请日：2022-03-01

Applicant: Children's Medical Center Corporation ,  The Technical University of Denmark ,  Dana-Farber Cancer Institute, Inc. ,  The Brigham and Women's Hospital, Inc.

Inventor： Zoltan SZALLASI ,  Nicolai Juul BIRKBAK ,  Aron EKLUND ,  Daniel SILVER ,  Zhigang WANG ,  Andrea RICHARDSON

IPC: C12Q1/6874 ,  C12Q1/6886

Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.

公开(公告)号：US11299782B2

公开(公告)日：2022-04-12

申请号：US16235247

申请日：2018-12-28

Applicant: Children's Medical Center Corporation ,  The Technical University of Denmark ,  Dana-Farber Cancer Institute, Inc. ,  The Brigham and Women's Hospital, Inc.

Inventor： Zoltan Szallasi ,  Nicolai Juul Birkbak ,  Aron Eklund ,  Daniel Silver ,  Zhigang Wang ,  Andrea Richardson

IPC: C12Q1/68 ,  C12P19/34 ,  C12Q1/6874 ,  C12Q1/6886

Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.

公开(公告)号：US20190309373A1

公开(公告)日：2019-10-10

申请号：US16404204

申请日：2019-05-06

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION ,  THE BRIGHAM AND WOMEN'S HOSPITAL, INC. ,  DANA-FARBER CANCER INSTITUTE, INC. ,  THE TECHNICAL UNIVERSITY OF DENMARK

Inventor： Zoltan I. Szallasi ,  Andrea L. Richardson ,  Nicolai J. Birkbak ,  Zhigang Wang

IPC: C12Q1/6886 ,  A61K31/704 ,  G01N33/574 ,  A61K33/24

Abstract: The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.

公开(公告)号：US20190136318A1

公开(公告)日：2019-05-09

申请号：US16235247

申请日：2018-12-28

Applicant: Children's Medical Center Corporation ,  The Technical University of Denmark ,  Dana-Farber Cancer Institute, Inc. ,  The Brigham and Women's Hospital, Inc.

Inventor： Zoltan SZALLASI ,  Nicolai Juul BIRKBAK ,  Aron EKLUND ,  Daniel SILVER ,  Zhigang WANG ,  Andrea RICHARDSON

IPC: C12Q1/6874 ,  C12Q1/6886

Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.

公开(公告)号：US10190160B2

公开(公告)日：2019-01-29

申请号：US14466208

申请日：2014-08-22

Applicant: Children's Medical Center Corporation ,  The Technical University of Denmark ,  Dana-Farber Cancer Institute, Inc. ,  The Brigham and Women's Hospital, Inc.

Inventor： Zoltan Szallasi ,  Nicolai Juul Birkbak ,  Aron Eklund ,  Daniel Silver ,  Zhigang Wang ,  Andrea Richardson

IPC: C12Q1/6886 ,  C12P19/34 ,  A61K38/00 ,  C07D487/00 ,  C12Q1/6874

Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.

公开(公告)号：US20160122827A1

公开(公告)日：2016-05-05

申请号：US14774772

申请日：2014-03-13

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION ,  THE BRIGHAM AND WOMEN'S HOSPITAL, INC. ,  DANA-FARBER CANCER INSTITUTE, INC. ,  THE TECHNICAL UNIVERSITY OF DENMARK

Inventor： Zoltan I. Szallasi ,  Andrea L. Richardson ,  Nicolai J. Birkbak ,  Zhigang Wang

IPC: C12Q1/68 ,  A61K31/704 ,  A61K33/24

CPC classification number: C12Q1/6886 ,  A61K31/704 ,  A61K33/24 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57415

Abstract: The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.

Abstract translation: 本发明提供了用于为具有增加的BML和FANCI基因表达的癌细胞和/或在癌细胞中染色体位置15q26具有拷贝数增加的癌症患者的子集的选择有效治疗的测定，方法和系统，并且用于治疗 这种患者根据个性化的癌细胞表达谱，对癌症患者进行有效的治疗。

公开(公告)号：US20150292033A1

公开(公告)日：2015-10-15

申请号：US14682545

申请日：2015-04-09

Applicant: Dana-Farber Cancer Institute, Inc. ,  Children's Medical Center Corporation ,  Brigham and Women's Hospital ,  The Technical University of Denmark

Inventor： Zhigang C. Wang ,  James Dirk Iglehart ,  Andrea L. Richardson ,  Zoltan Szallasi ,  Nicolai Juul Birbak ,  Ursula Matulonis

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/156

Abstract: Provided is a method of predicting the prognosis of a patient with ovarian cancer by determining the total number of somatic exome mutations per genome (Nmut) and status of the BRCA1 and/or BRCA2 in the subject.

Abstract translation: 提供了通过确定受试者中每个基因组的体细胞外显子突变（Nmut）和BRCA1和/或BRCA2的状态的总数来预测患有卵巢癌患者的预后的方法。

公开(公告)号：US20150038340A1

公开(公告)日：2015-02-05

申请号：US14466208

申请日：2014-08-22

Applicant: Children's Medical Center Corporation ,  The Technical University of Denmark ,  Dana-Farber Cancer Institute, Inc. ,  The Brigham and Women's Hospital, Inc.

Inventor： Zoltan Szallasi ,  Nicolai Juul Birkbak ,  Aron Eklund ,  Daniel Silver ,  Zhigang Wang ,  Andrea Richardson

IPC: C12Q1/68

CPC classification number: C12Q1/6874 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2800/52

Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.

Abstract translation: 本发明部分地基于鉴定用于定义对抗癌药物的响应的预测生物标志物的新方法。